Cargando…
The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction
AIMS: Although inflammation plays an important role in the pathogenesis of heart failure (HF), the precise pathophysiological role of inflammation in HF with preserved left ventricular ejection fraction (HFpEF) still remains unclear. Hence, we examined the clinical significance of plasma neopterin,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063166/ https://www.ncbi.nlm.nih.gov/pubmed/27774267 http://dx.doi.org/10.1002/ehf2.12070 |
_version_ | 1782459920965173248 |
---|---|
author | Yamamoto, Eiichiro Hirata, Yoshihiro Tokitsu, Takanori Kusaka, Hiroaki Tabata, Noriaki Tsujita, Kenichi Yamamuro, Megumi Kaikita, Koichi Watanabe, Hiroshi Hokimoto, Seiji Maruyama, Toru Ogawa, Hisao |
author_facet | Yamamoto, Eiichiro Hirata, Yoshihiro Tokitsu, Takanori Kusaka, Hiroaki Tabata, Noriaki Tsujita, Kenichi Yamamuro, Megumi Kaikita, Koichi Watanabe, Hiroshi Hokimoto, Seiji Maruyama, Toru Ogawa, Hisao |
author_sort | Yamamoto, Eiichiro |
collection | PubMed |
description | AIMS: Although inflammation plays an important role in the pathogenesis of heart failure (HF), the precise pathophysiological role of inflammation in HF with preserved left ventricular ejection fraction (HFpEF) still remains unclear. Hence, we examined the clinical significance of plasma neopterin, an inflammatory biomarker, in HFpEF patients. METHODS AND RESULTS: In the present study, we recruited consecutive HFpEF patients hospitalized in Kumamoto University Hospital, and further measured plasma neopterin by high‐performance liquid chromatography and serum derivatives of reactive oxidative metabolites (DROM), a new biomarker of reactive oxygen species. Compared with risk factors (number of patients, age, sex, and equal incidence of diabetes mellitus, hypertension, and dyslipidemia) ‐matched non‐HF patients (n = 68), plasma neopterin levels, but not serum high‐sensitivity C‐reactive protein levels, were significantly increased in patients with HFpEF (n = 68) (P < 0.001 and P = 0.15, respectively), accompanied by an elevation in serum DROM levels (P < 0.001). Plasma neopterin levels in New York Heart Association (NYHA) class III/IV HFpEF patients were significantly higher than in NYHA class II patients (P < 0.004). Furthermore, plasma ln‐neopterin levels had significant and positive correlation with ln‐DROM values (r = 0.57) and parameters of cardiac diastolic dysfunction [the ratio of early transmitral flow velocity to tissue Doppler early diastolic mitral annular velocity (r = 0.34), left atrial volume index (r = 0.17), and B‐type natriuretic peptide (r = 0.38)]. Kaplan–Meier analysis showed that the high‐neopterin group (>51.5 nM: median value of neopterin in HFpEF patients) had a higher probability of cardiovascular events than the low‐neopterin group (log‐rank test, P = 0.003). CONCLUSIONS: Plasma neopterin levels significantly increased in HFpEF and correlated with the severity of HF. Furthermore, high neopterin were significantly correlated with future cardiovascular events, indicating that measurement of plasma neopterin might provide clinical benefits for risk stratification of HFpEF patients. © 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. |
format | Online Article Text |
id | pubmed-5063166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50631662016-10-19 The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction Yamamoto, Eiichiro Hirata, Yoshihiro Tokitsu, Takanori Kusaka, Hiroaki Tabata, Noriaki Tsujita, Kenichi Yamamuro, Megumi Kaikita, Koichi Watanabe, Hiroshi Hokimoto, Seiji Maruyama, Toru Ogawa, Hisao ESC Heart Fail Short Communications AIMS: Although inflammation plays an important role in the pathogenesis of heart failure (HF), the precise pathophysiological role of inflammation in HF with preserved left ventricular ejection fraction (HFpEF) still remains unclear. Hence, we examined the clinical significance of plasma neopterin, an inflammatory biomarker, in HFpEF patients. METHODS AND RESULTS: In the present study, we recruited consecutive HFpEF patients hospitalized in Kumamoto University Hospital, and further measured plasma neopterin by high‐performance liquid chromatography and serum derivatives of reactive oxidative metabolites (DROM), a new biomarker of reactive oxygen species. Compared with risk factors (number of patients, age, sex, and equal incidence of diabetes mellitus, hypertension, and dyslipidemia) ‐matched non‐HF patients (n = 68), plasma neopterin levels, but not serum high‐sensitivity C‐reactive protein levels, were significantly increased in patients with HFpEF (n = 68) (P < 0.001 and P = 0.15, respectively), accompanied by an elevation in serum DROM levels (P < 0.001). Plasma neopterin levels in New York Heart Association (NYHA) class III/IV HFpEF patients were significantly higher than in NYHA class II patients (P < 0.004). Furthermore, plasma ln‐neopterin levels had significant and positive correlation with ln‐DROM values (r = 0.57) and parameters of cardiac diastolic dysfunction [the ratio of early transmitral flow velocity to tissue Doppler early diastolic mitral annular velocity (r = 0.34), left atrial volume index (r = 0.17), and B‐type natriuretic peptide (r = 0.38)]. Kaplan–Meier analysis showed that the high‐neopterin group (>51.5 nM: median value of neopterin in HFpEF patients) had a higher probability of cardiovascular events than the low‐neopterin group (log‐rank test, P = 0.003). CONCLUSIONS: Plasma neopterin levels significantly increased in HFpEF and correlated with the severity of HF. Furthermore, high neopterin were significantly correlated with future cardiovascular events, indicating that measurement of plasma neopterin might provide clinical benefits for risk stratification of HFpEF patients. © 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. John Wiley and Sons Inc. 2015-11-09 /pmc/articles/PMC5063166/ /pubmed/27774267 http://dx.doi.org/10.1002/ehf2.12070 Text en © 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Short Communications Yamamoto, Eiichiro Hirata, Yoshihiro Tokitsu, Takanori Kusaka, Hiroaki Tabata, Noriaki Tsujita, Kenichi Yamamuro, Megumi Kaikita, Koichi Watanabe, Hiroshi Hokimoto, Seiji Maruyama, Toru Ogawa, Hisao The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
title | The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
title_full | The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
title_fullStr | The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
title_full_unstemmed | The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
title_short | The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
title_sort | clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063166/ https://www.ncbi.nlm.nih.gov/pubmed/27774267 http://dx.doi.org/10.1002/ehf2.12070 |
work_keys_str_mv | AT yamamotoeiichiro theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT hiratayoshihiro theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT tokitsutakanori theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT kusakahiroaki theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT tabatanoriaki theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT tsujitakenichi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT yamamuromegumi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT kaikitakoichi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT watanabehiroshi theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT hokimotoseiji theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT maruyamatoru theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT ogawahisao theclinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT yamamotoeiichiro clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT hiratayoshihiro clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT tokitsutakanori clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT kusakahiroaki clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT tabatanoriaki clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT tsujitakenichi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT yamamuromegumi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT kaikitakoichi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT watanabehiroshi clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT hokimotoseiji clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT maruyamatoru clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction AT ogawahisao clinicalsignificanceofplasmaneopterininheartfailurewithpreservedleftventricularejectionfraction |